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Abstract 
We have isolated parcas (pcs) in a screen to identify novel regulators of muscle morphogenesis. Pcs is expressed in the ovary and oocyte 
during oogenesis and again in the embryo, specifically in the developing mesoderm, throughout muscle development. pcs is first required in the 
ovary during oogenesis for patterning and segmentation of the early Drosophila embryo due primarily to its role in the regulation of Oskar (Osk) 
levels. In addition to the general patterning defects observed in embryos lacking maternal contribution of pcs, these embryos show defects in 
Wingless (Wg) expression, causing losses of Wg-dependent cell types within the affected segment. pcs activity is required again later during 
embryogenesis in the developing mesoderm for muscle development. Loss and gain of function studies demonstrate that pcs is necessary at 
distinct times for muscle specification and morphogenesis. Pcs is predicted to be a novel regulator of non-receptor tyrosine kinase (NRTK) 
signaling. We have identified one target of Pcs regulation, the Drosophila Tec kinase Btk29A. While Btk29A appears to be regulated by Pcs 
during its early role in patterning and segmentation, it does not appear to be a major target of Pcs regulation during muscle development. We 
propose that Pcs fulfils its distinct roles during development by the regulation of multiple NRTKs. 
© 2006 Elsevier Inc. All rights reserved. Keywords: Parcas; Oskar; Wingless; Btk29A; Non-receptor tyrosine kinase signaling; Mesoderm; Muscle; Morphogenesis Introduction 
A common theme throughout the development of all 
multicellular organisms is the redeployment of individual 
genes or gene cassettes at different times and places. Genes 
may be required for development of several tissues within an 
organism or at multiple times within development of a specific 
tissue. One model system that has proved highly fruitful in the 
study of pleiotrophic genes is Drosophila melanogaster due to 
the power of both classical genetics and clonal analysis. In 
particular, this system has allowed the identification of several 
signaling pathways that are used reiteratively throughout 
development (Lai, 2004; Simon, 2000). Although much is 
now known about the molecular components that build these 
signaling pathways, how time and tissue context affect their final ⁎ Corresponding author. Fax: +1 646 422 2355.
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the output of signaling pathways may be influenced by positive 
and negative regulatory proteins that are expressed in a temporal 
and tissue specific manner (e.g. Panin and Irvine, 1998). 
The mesoderm of the Drosophila embryo has provided an 
excellent system to study the reiterative use of signaling 
pathways during development (Baylies and Michelson, 2001; 
Baylies et al., 1998; Frasch, 1999). This germ layer gives rise to 
a number of tissues, most notably the larval body wall muscles, 
through the integration of multiple signal transduction path­
ways. There are thirty body wall muscles in each embryonic 
hemisegment. Each body wall muscle has a unique size, shape, 
orientation, attachment sites in the epidermis, and innervation 
by the nervous system. Body wall muscles arise from two cell 
types specified in the somatic mesoderm, founder cells (FCs) 
and fusion competent myoblasts (FCMs). FCs contain all the 
information required to form an individual muscle (Bate, 1990; 
Dohrmann et al., 1990). Upon fusion to an FC, FCMs become 
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 entrained to that particular muscle program. The identification 
of FCM-enriched genes that regulate muscle morphogenesis, 
however, suggested that FCMs may not be the naive cell type 
that previous studies have indicated (Artero et al., 2003; Estrada 
et al., 2006). In addition, other observations have suggested that 
FCMs are not a uniform population of myoblasts (Artero et al., 
2001; Estrada et al., 2006; Ruiz-Gomez et al., 2002). For 
example, hibris (hbs), an Ig-domain containing protein required 
for fusion, is expressed only in a subset of FCMs (Artero et al., 
2001). Together, these data indicated that FCMs are a diverse 
population of myoblasts that contribute specific information to 
muscle fusion and morphogenesis. 
We identified parcas (pcs; also known as poirot) in a
microarray screen to identify novel genes required for muscle 
morphogenesis (Artero et al., 2003). Data from the microarray 
screen predicted that Pcs would be enriched in FCMs and was 
likely to be important in muscle morphogenesis. Pcs is the 
Drosophila orthologue of the mammalian gene Sab. Sab (SH3­
domain binding protein that preferentially associates with Btk) 
was identified as a novel protein that binds to the SH3 domain of 
BTK (Bruton's tyrosine kinase) in vitro (Matsushita et al., 
1998). Sab associates with BTK in vivo and negatively regulates 
its activation (Yamadori et al., 1999), but the mechanism of this 
regulation is not well understood. BTK is a member of a family 
of non-receptor tyrosine kinases called Tec kinases. These 
kinases play roles in multiple processes including cell survival, 
proliferation, differentiation, and cytoskeletal regulation (Lewis 
et al., 2001; Smith et al., 2001). There is only one member of this 
family of proteins in Drosophila, Btk29A (also known as 
Tec29). The principle role of this protein in Drosophila 
development to date is in regulation of the actin cytoskeleton 
during ring canal growth in oogenesis, cellularization, salivary 
gland invagination, and dorsal closure (Chandrasekaran and 
Beckendorf, 2005; Guarnieri et al., 1998; Roulier et al., 1998; 
Tateno et al., 2000; Thomas and Wieschaus, 2004). 
Previous studies on Pcs have focused on its role and 
interaction with Btk29A during oogenesis (Sinka et al., 2002). 
These studies demonstrated that Pcs is required for the 
specification of posterior cell types during anterior–posterior 
(A–P) patterning early during embryogenesis. The establish­
ment of A–P polarity in early Drosophila embryos depends 
upon gradients of maternally deposited factors (Johnstone and 
Lasko, 2001; Riechmann and Ephrussi, 2001). One of these 
factors, Nanos (Nos), is specifically required to determine 
posterior structures within the embryo (Lehmann and Nusslein-
Volhard, 1991; Wang and Lehmann, 1991). Nos protein is 
distributed in a gradient along the A–P axis of the embryo, with 
its highest levels at the posterior pole. This gradient of Nos is 
due to the specific translation of its transcript at the posterior 
pole of the embryo by multiple factors, including the protein 
Oskar (Osk), and the subsequent diffusion of Nos protein away 
from its source (Gavis and Lehmann, 1992; Wang et al., 1994). 
For Osk to localize nos to the posterior pole of the embryo, it 
too has to be localized correctly (Ephrussi et al., 1991). 
Although osk mRNA is localized posteriorly during oogenesis, 
it is the translation and post-translational regulation of this 
transcript that has been shown to establish wild type osk activity at the posterior pole. Several genes have been identified that are 
required specifically for the localization of Osk protein 
(Jankovics et al., 2001, 2002). Of these, pcs is required for 
localization of Osk protein, but not its mRNA. Embryos laid by 
pcs homozygous mutant mothers showed a reduction and 
delocalization of Osk (Sinka et al., 2002). As a result, these 
embryos lack the most posterior structures of the embryo, the 
pole cells, and therefore are sterile. 
Here, we report that pcs is used reiteratively during 
development of the Drosophila embryo and that these different 
roles have significant ramifications for the development of the 
larval body wall muscles. First, pcs is required maternally to 
establish correct anterior–posterior patterning, which in turn 
regulates subsequent mesoderm development. This appears to 
be due primarily to the role of Pcs in regulation of Osk 
expression levels during oogenesis. Embryos lacking maternal 
pcs expression show disruptions in embryonic patterning. A 
subset of these defects are due to losses of Wingless (Wg) 
expression and thus the specification of Wg-dependent cell 
types within the developing embryo. Second, we show that pcs 
is required later, specifically in the mesoderm, for both muscle 
specification and morphogenesis. This requirement for Pcs at 
several steps of muscle development is consistent with its 
expression in the mesoderm throughout muscle development. 
While the Drosophila Tec kinase Btk29A appears to be the 
major target of Pcs regulation during early patterning events, we 
also demonstrate a lack of Btk29A expression and activity 
during muscle development, suggesting that Pcs has additional 
targets. We therefore propose that Pcs fulfils these different 
roles during embryonic development by regulating the activity 
of multiple non-receptor tyrosine kinases. 
Materials and methods 
Drosophila genetics 
Crosses were performed at 25°C unless otherwise stated. yw was used as the 
wild type strain. Fly stocks were: pcsgs (provided by M. Erdélyi); N55e11 and 
UAS-Nintra (provided by T. Lieber); UAS-rasN17 , UAS-rasV12, and twi-GAL4; 
Dmef2-GAL4 (provided by A. Michelson); Btk29Ak00206 (Roulier et al., 1998); 
rP298 (Ruiz-Gomez et al., 2000); twi-CD2 (Borkowski et al., 1995); prd-GAL4 
(Brand and Perrimon, 1993); UAS-ΔNTCF (van de Wetering et al., 1997), 
oskM139L, osk54, and Df(3R)pXT103 (a gift from Anne Ephrussi). osk301 is a 
temperature sensitive allele. Embryos laid by females homozygous for this allele 
at 18°C show posterior localization of osk mRNA and weak abdominal defects. 
oskCE4 is a stronger allele, and embryos laid by females homozygous for this 
allele show no osk mRNA at the posterior pole and are agametic (Ephrussi et al., 
1991). OskM139L is a transgene that expresses the long isoform of Osk only 
(Markussen et al., 1995). osk54 contains a nonsense codon in the amino-terminal 
region and does not produce any Osk protein. Df(3R)pXT103 uncovers osk 
(Kim-Ha et al., 1991). Combinations of mutations and stocks required for 
overexpression experiments were generated by standard genetic crosses at 25°C. 
For phenotypic studies, relevant stocks were balanced with CyO P[w+ ftz-lacZ], 
TM3 Sb Ubx-lacZ or FM7 P[w+ ftz-lacZ]. GAL4/UAS experiments were 
performed at 25°C or 29°C as noted. 
Germline transformation and constructs 
Pcs protein was overexpressed using the GAL4/UAS system (Brand and 
Perrimon, 1993). Full length pcs cDNA (GH09755) was subcloned into 
pBluescript SK+ (pBS) by PCR using 5′ primers containing a SmaI site 
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(CCGGAATTCACTATTCCAGAGAGCG). This pcs cDNA was subcloned 
from pBS into the overexpression construct pUAST using XbaI and EcoRI. The 
pcs RNAi construct was made by first subcloning a 500 bp fragment of GFP 
DNA downstream of the pcs cDNA in pBS-pcs using HindIII. The second copy 
of the pcs cDNA was subcloned into this construct by PCR using 5′ primers 
containing a KpnI site (CGGGGTACCACTATTCCAGAGAGCG) and 3′ 
primers containing a XhoI site (CCGCTCGAGAATGTCGAGT). This resulted 
in pBS containing the full length pcs cDNA, a 500 bp GFP linker, and the full 
length pcs cDNA cloned in the opposite orientation. This entire insert was then 
subcloned into pUAST using KpnI and XbaI. Upon expression, this transcript 
double-backs upon itself forming a hairpin double-stranded RNA that can be 
processed for RNAi (Piccin et al., 2001). Both constructs were injected into yw 
embryos according to published transgenic procedures (Baylies and Bate, 1996). 
Generation of Pcs polyclonal antibody 
The full length pcs cDNA was cloned into pGEX-2T, and Glutathione S-
transferase (GST) fusion proteins were produced in DH5α E. coli using standard 
induction conditions. GST-Pcs proteins were purified by Glutathione Sepharose 
beads according to manufacturer's instructions (Amersham Pharmacia Biotech) 
and concentrated using Centriprep centrifugal filter devices (Millipore). This 
bacterially expressed and purified GST-Pcs was injected into rabbits at Pocono 
Rabbit Farm and Laboratory (Canandensis, PA), according to standard 
protocols. We confirmed antibody specificity by performing Western blots on 
protein extracts from wild type and pcsgs mutant adults (Supplementary Fig. 
1A). As previously described, Pcs protein is detected as a 53–55 kDa doublet 
(Sinka et al., 2002). This doublet is absent in protein extracts made from adults 
lacking Pcs expression indicating the specificity of the anti-Pcs antiserum to Pcs 
protein. 
Immunohistochemistry 
Immunocytochemistry in embryos was performed as described by Artero et 
al. (2003), with the following modifications. Antibodies were preabsorbed (PA) 
against fixed yw embryos or in combination with the TSA system (TSA; 
PerkinElmer Life Sciences). Antibody dilutions were: anti-Mhc (1:10,000; TSA; 
a gift from D. Kiehart), anti-Kr (1:2000; PA; provided by J. Reinitz), anti-Eve 
(1:3000; PA), anti-Wg (1:500; PA; Developmental Studies Hybridoma Bank), 
anti-FasIII (1:100), anti-Twi (1:5000; PA; a gift from S. Roth), anti-Zfh1 
(1:5000; provided by Z.C. Lai), anti-β-gal (1:2000; Promega), anti-Osk 
(1:12,000; provided by A. Ephrussi), anti-Lmd (1:1500; PA; provided by H. 
Nguyen), and anti-Pcs (1:500; PA). Biotinylated secondary antibodies were used 
in combination with Vector Elite ABC kit (Vector Laboratories, CA). Specimens 
were embedded in Araldite and images captured using an Axiocam camera 
(Zeiss) using Adobe Photoshop software. Fluorescent immunocytochemistry 
using anti-Pcs (1:6000; PA) was detected with the TSA-FITC system 
(PerkinElmer Life Sciences). Anti-β-gal (1:1000; Promega), anti-CD2 
(1:10,000; Serotec), anti-Tec29 (1:10; provided by S. Beckendorf), anti-Twi 
(1:1000; PA; a gift from S. Roth), and anti-Mhc (1:1000) were detected using 
Cy3- or FITC-conjugated secondaries and analyzed using a Zeiss LSM510 
confocal microscope. Pcs RNA localization was detected using digoxigenin­
labeled RNA probes, as described (O'Neill and Bier, 1994). 
Western blot analysis 
Whole adults or bleach-dechorionated embryos were processed in 2× 
Laemmli's sample buffer (125 mM Tris–HCl, pH 6.8, 20% glycerol, 4% SDS, 
and Bromophenol blue). Extract equivalents of approximately 3 adults or 10 
embryos were loaded per lane on 10% SDS-PAGE gels. Proteins were 
transferred to PVDF membrane (Amersham Biosciences) at 60 V for 90 min in 
cold transfer buffer (10 mM CAPS, pH 11, 10% methanol). Benchmark 
Prestained Protein Ladder (GibcoBRL) was used as a molecular weight marker. 
Blots were blocked using 5% dry milk in TBST and incubated with anti-Pcs 
antibody diluted 1:1000 (preabsorbed against yw embryos) and anti-α-tubulin 
(Accurate Chemical and Scientific Corporation) diluted 1:500 in 5% dry milk in 
TBST. Membranes were washed in 5% dry milk in TBST and incubated with peroxidase-conjugated anti-rabbit (for Pcs; Sigma) or donkey anti-rat (for α­
tubulin; Accurate Chemical and Scientific Corporation) secondary antibodies in 
5% dry milk in TBST. Signals were detected with enhanced chemiluminescence 
(Amersham Biosciences). Results 
Pcs is expressed in the mesoderm and enriched specifically in 
FCMs 
A previous study has described Pcs expression during 
oogenesis (Sinka et al., 2002). Since our screen suggested a role 
for Pcs during muscle development, we focused on the 
embryonic expression pattern of Pcs protein. Immunocyto­
chemistry revealed that Pcs is expressed in the mesoderm 
throughout embryogenesis (Figs. 1A–C). Pcs protein was 
detected in the mesoderm at stage 10 as the mesoderm is 
allocated into different tissues (Fig. 1A). At stage 11, Pcs is 
strongly expressed in the visceral and somatic mesoderm during 
FC and FCM specification (Fig. 1B). From stage 12 to the end 
of embryogenesis, Pcs was expressed at high levels in the 
somatic mesoderm as myoblasts fuse and muscles achieve their 
final morphology (Fig. 1C). Pcs expression in the visceral 
mesoderm diminishes during these stages, and Pcs protein is not 
detected in the final muscles (data not shown). Expression of 
pcs mRNA in wild type embryos was also analyzed. This 
expression mirrored that of Pcs protein during the early stages 
of mesoderm and somatic mesoderm development, except that 
pcs mRNA was detected in the mesoderm slightly earlier, 
from stage 9 onwards (data not shown). 
Our previous microarray and Northern blot analysis focused 
on pcs expression during FC and FCM specification and 
predicted that pcs is particularly enriched in FCMs (Artero et 
al., 2003). To confirm this prediction, we tested whether pcs 
expression levels correlated with the number of FCMs specified 
(Figs. 1D–I). First, we analyzed pcs expression levels when 
FCM number was decreased either by decreasing Notch (N) 
signaling or increasing Ras signaling (Artero et al., 2001; Bour 
et al., 2000; Carmena et al., 2002). In embryos lacking all 
zygotic N expression, reduced FCM numbers are detected and a 
corresponding reduction in pcs levels was found (Fig. 1E). 
Likewise, when FCM numbers were reduced by increasing Ras 
signaling in the mesoderm by overexpressing an activated form 
of the Ras protein (RasV12), a decrease in pcs mRNA levels in 
the mesoderm was detected (Fig. 1F). We next increased FCM 
numbers by activating N signaling (by overexpressing an 
activated form of the N receptor [Nintra]) or by reducing Ras 
signaling (by overexpressing a dominant negative form of Ras 
[RasN17]) in the mesoderm (Artero et al., 2001; Carmena et al., 
2002). In both cases, an increase in FCM number was found 
with a concomitant increase in pcs expression levels (Figs. 1G– 
I). However, increasing N signaling increased pcs levels much 
more than decreasing Ras signaling, suggesting that pcs 
expression may be directly regulated by N signaling in FCMs. 
Indeed, sequence analysis has identified several potential 
Suppressor of Hairless (Su(H)) binding sites in the first intron 
of the parcas gene (data not shown). Together, these data 
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Fig. 1. Pcs is expressed in the developing mesoderm and specifically enriched in FCMs. In all panels, anterior is left and dorsal is up. Staging is according to Campos-
Ortega and Hartenstein (1985) in all figures. (A) At stage 10, Pcs is expressed throughout the mesoderm. This expression continues to stage 11 (B) where it is expressed 
in the somatic (black arrow), cardiac, and visceral mesoderm (white arrow). (C) Pcs is expressed in the somatic mesoderm throughout myoblast fusion and muscle 
morphogenesis (black arrow, stage 14). (D–I) Pcs expression levels at stage 11 correlate with the number of FCMs specified. (D, G) Pcs is expressed at moderate levels 
in the mesoderm at stage 11. (E, I) Decreasing the number of FCMs specified by using an N mutant embryo (E) or expressing an activated form of the Ras protein 
(UAS-RasV12) throughout the mesoderm (I) causes a decrease in pcs levels. Increasing the number of FCMs specified by expressing a constitutively activated form of 
the N receptor (UAS-N intra; F) or a dominant negative form of Ras (UAS-RasN17; H) causes an increase in pcs levels. (J–L) Pcs is enriched in FCMs. The panels shown 
are close-ups of the ventral–lateral somatic mesoderm. Anti-Pcs (green), anti-β-Gal (red nuclear), and anti-CD2 (red membrane) staining and merges are shown in 
stage 12 (J, K) and stage 14 (L) rP298; twi-CD2 embryos. The enhancer trap insertion rP298 marks FCs in somatic and visceral mesoderm (Ruiz-Gomez et al., 2000). 
Twi-CD2 labels the plasma membrane of all FCs and FCMs (Borkowski et al., 1995). Panels J and K show two optical sections from a single z-stack. Panel J shows the 
most external layer of mesodermal cells, while panel K is more interior. Pcs is expressed in FCMs surrounding FCs (white arrows, J). However, low levels of Pcs 
expression are observed in a single ventral FC (white arrow, K) and lateral FC (data not shown). Pcs expression is absent from all other FCs at this stage (white 
arrowhead, K). (L) Pcs is enriched in FCMs throughout the fusion process. At stage 14, Pcs is enriched in FCMs (white arrows, L) and completely absent from growing 
myotubes (white arrowheads, L). Pcs expressing FCMs can be observed lining up alongside the myotube that will form muscle VA1 (white asterisk, L). indicated that pcs expression in the mesoderm at the time of FC 
and FCM specification correlated with the numbers of FCMs 
specified. These data supported the prediction that pcs is 
enriched in FCMs at this stage of development. 
To further examine the FCM expression and cellular 
localization of Pcs, we analyzed Pcs expression in the 
mesoderm using fluorescent immunocytochemistry. We per-
formed these experiments in embryos expressing rP298, which 
is a lacZ-containing P element insertion into the dumbfounded 
(duf) gene and labels the nuclei of all FCs (Ruiz-Gomez et al., 
2000), and a mesodermal reporter gene (twi-CD2), which labels 
the membranes of all FCs and FCMs (Borkowski et al., 1995). 
These rP298; twi-CD2 embryos were simultaneously labeled with antibodies to β-galactosidase, CD2, and Pcs. In these 
embryos, we identified FCs by the expression of rP298 and twi­
CD2 and all FCMs by expression of twi-CD2 and lack of rP298. 
We detected low levels of Pcs expression throughout the 
somatic mesoderm at stage 11 (data not shown). However, by 
stage 12, Pcs expression is strongly upregulated in all FCMs 
(Figs. 1J, K). Pcs expression was also observed at low levels in a 
single ventral (Fig. 1K) and lateral (data not shown) FC at this 
stage of development. However, we have been unable to 
determine the identity of these FCs using available markers. 
This limited FC expression is transient as no Pcs expression was 
observed in growing myotubes (Fig. 1L). As myoblast fusions 
proceed, Pcs expression is maintained at high levels in all FCMs 
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was enriched in the cytoplasm and at the cell membranes of 
FCMs (Figs. 1J–L). These data indicated that Pcs is expressed 
throughout the somatic mesoderm at the time of mesodermal 
patterning and FC specification, while later during muscle 
morphogenesis it is specifically expressed in FCMs. 
Embryos lacking all maternal and zygotic expression of pcs 
show defects in mesodermal patterning, muscle specification 
and muscle morphogenesis 
The specific expression of Pcs during several distinct periods 
of mesoderm and somatic muscle development implied that pcs 
may play important roles in regulating these processes. We 
tested this hypothesis first by analyzing muscle development in 
embryos lacking all pcs expression. Flies homozygous for a 
null allele of pcs (pcs gs) are adult viable with reduced egg-
laying capacity. We therefore collected embryos laid by pcs 
homozygous mutant females crossed to pcs homozygous 
mutant males. These embryos lacked all maternal and zygotic 
expression of pcs and are referred to as pcs gs m+z embryos. 
Wild type embryos have a segmentally repeated, distinct 
array of 30 muscles per hemisegment (Figs. 2A, C and 6A, D, 
G). In pcs gs m+z embryos, one third of these embryos show a 
severe muscle phenotype including the absence of many 
muscles, large numbers of unfused myoblasts present often 
where a missing muscle should be located, and defects in 
muscle morphology (n =32). Muscles, although specified, were 
often not the correct size, shape, and orientation and attached 
incorrectly to the overlaying epidermis (Figs. 2B, D and 6B, E, 
H). In addition, we observed that the posterior segments were 
most often affected (Fig. 6H). The severity of these muscle 
defects is variable. While one third of embryos show a severe 
muscle phenotype, the remaining embryos display only mild to 
moderate defects in the final muscle pattern. This variability is 
true for all the phenotypes described below. In addition, only 
60% of moderately to severely affected embryos (n =27) 
displayed a large number of unfused myoblasts. These unfused 
myoblasts are predominantly in segments lacking many 
muscles (data not shown). Given these phenotypes and the 
mesodermal expression of Pcs described above, we hypothe­
sized that pcs may be required for normal muscle development 
to occur. We therefore analyzed earlier steps of muscle 
development in these mutant embryos to determine the cause 
of these muscle phenotypes and correlate these defects with Pcs 
expression. 
A likely explanation for the observed increase in unfused 
myoblasts, particularly in the light of the observed missing 
muscles, was that FCs were not being correctly specified, 
leading to FCMs with no FC with which to fuse. Thus, two FC 
markers, Even-skipped (Eve) and Krüppel (Kr), were used to 
analyze FC specification in pcs gs m+z mutant embryos. In 
wild type embryos, Eve is expressed in a discrete cluster of 
cells in the dorsal mesoderm of each hemisegment that will 
form the dorsal DA1 muscle and two pericardial cells (Fig. 2E) 
(Carmena et al., 1998). In pcs gs m+z mutant embryos, we 
observed frequent disruptions of Eve expression, indicating a loss of Eve-positive FCs (Fig. 2F). This Eve expression loss 
corresponded with an absence of the Eve-expressing dorsal 
muscle DA1 (Fig. 6H) and pericardial cells (data not shown) 
later in development. Kr is normally expressed in a subset of 
FCs in the dorsal, lateral, and ventral mesoderm (Fig. 2G) 
(Ruiz-Gomez et al., 1997). However, in pcs gs m+z mutant 
embryos, occasional losses of Kr expressing FCs were 
observed (Fig. 2H). Together, these data revealed that pcs gs 
m+z mutant embryos have defects in FC specification that 
most likely account for the muscle losses observed in the final 
muscle pattern. 
Since Pcs is not expressed, for example, in Eve-expressing 
FCs (data not shown), but is expressed prior to FC specification, 
we investigated whether these FC losses could be due to an 
earlier defect in mesodermal patterning. Therefore, we analyzed 
early mesodermal patterning in pcs gs m+z mutant embryos. In 
wild type embryos, Twist is expressed in all mesodermal cells at 
high levels at stage 9 (Fig. 2I) and is necessary for mesodermal 
specification (Thisse et al., 1987). Subsequently, Twist levels 
are modulated at stage 10, when Twist is required for allocation 
of mesoderm into its different tissue types (Baylies and Bate, 
1996). In pcs gs m+z mutant embryos, we observed reduced 
Twist levels as well as a “twisted” phenotype, reminiscent of the 
phenotype displayed by twist mutant embryos (Fig. 2J) (Thisse 
et al., 1987). The number of Twist-expressing cells appears to 
be normal. Given this effect on Twist expression, we also 
determined if mesodermal tissues other than body wall muscles 
were affected. Wild type embryos stained with an antibody 
against Fasciclin III (FasIII) show a stripe of FasIII-positive 
cells along the A–P axis of the embryo that will eventually form 
the gut muscles of the embryo (Fig. 2K) (Baylies and Bate, 
1996). In pcs gs m+z mutant embryos, we observed gaps in 
FasIII staining, indicating a loss of visceral mesoderm (Fig. 2L). 
The presence of cardiac mesoderm was assayed using the 
marker Zinc Finger Homeodomain 1 (Zfh1), which is expressed 
in four rows of cells, cardioblasts, and pericardial cells, along 
the dorsal side of the embryo (Fig. 2M) (Lai et al., 1991). In 
pcs gs m+z mutant embryos, Zfh1-positive cells were missing, 
indicating a loss of cardiac mesoderm (Fig. 2N). Hence, the 
phenotypic analysis indicated that pcs gs m+z mutant embryos 
show defects at two steps of muscle development. First, these 
embryos showed defects in early mesodermal patterning. Pcsgs 
m+z mutant embryos showed an early reduction in Twist 
expression levels (Fig. 2J) and a concomitant decrease in 
somatic, visceral, and cardiac lineages (Figs. 2B, D, F, H, J, L, 
N). Second, these embryos show defects in muscle morphogen­
esis. In the muscles that are specified in pcs gs m+z mutant 
embryos, a number of morphological defects are observed 
including defects in muscle size, shape, and orientation (Figs. 
2B, D and 6A, D, G). 
Pcs is required during oogenesis for posterior patterning and 
segmentation 
Although the phenotypic analysis of pcs gs m+z mutant 
embryos suggested that Pcs may play multiple roles in muscle 
development, we found additional defects in segmentation and 
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Fig. 2. Pcsgs m+z mutant embryos display defects in muscle development, mesodermal patterning, segmentation, and early patterning events. Anterior is left and 
dorsal is up unless otherwise noted. All views are lateral except for panels A–D, O, P, U, and V, which are ventral or panels M, N, W, and X, which are dorsal. Wild type 
and pcsgs m+z mutant embryos were stained with antibodies against MHC (A–D), Eve (E, F, O, P, S, T), Kr (G, H, Q, R), Twi (I, J), FasIII (K, L), Zfh1 (M, N), and Wg 
(U–X). (A–N) Pcs is required for the specification and patterning of mesodermal tissues. (A–D) pcsgs m+z mutant embryos show losses of muscles (black arrow, B, 
D), unfused myoblasts (black arrowhead, B, D) and defects in muscle morphology (white arrow, B, D). (E–H) Pcs is required for FC specification. (E) In stage 11 wild 
type embryos, Eve is expressed in a subset of FCs in the dorsal mesoderm of each hemisegment. (F) Pcsgs m+z mutant embryos show losses of Eve expression (black 
arrow, F). (G) Kr is expressed in a subset of dorsal, lateral, and ventral FCs in stage 12 wild type embryos. (H) Losses of Kr expressing FCs are observed in pcsgs m+z 
mutant embryos (black arrows, H). (I–N) Pcsgs m+z mutant embryos display general mesodermal patterning defects. (I) Twi is expressed at high levels in all 
mesodermal cells at stage 9 in wild type embryos, while pcsgs m+z mutant embryos show a reduction in Twi expression levels and aberrant mesodermal patterning (J). 
(K, L) Losses of visceral mesoderm at stage 11 are also detected in pcsgs m+z mutant embryos as shown by gaps in FasIII staining (black arrow, L). The embryo shown 
displays a relatively subtle phenotype with only small gaps in FasIII staining. More severely affected embryos show more dramatic losses of visceral mesoderm. (M, 
N) Pcsgs m+z mutant embryos show losses of cardiac mesoderm as indicated by losses of Zfh-1 positive cardioblasts at stage 16 (black arrow, N). (O–X) Pcs is 
required for early patterning and segmentation. (O, P) Pcsgs m+z mutant embryos show losses of neurons in the CNS as shown by loss of Eve-expressing cells in the 
ventral nerve cord at stage 16 (black arrow, P). (Q) The gap gene Kr expressed a distinct domain in the center of the embryo at blastoderm stages (black bracket, Q). 
This domain of Kr expression is expanded in pcsgs m+z mutant embryos (black bracket, R). (S) The pair-rule gene Eve is expressed in seven stripes along the A–P axis 
of the blastoderm embryo. (T) Pcsgs m+z mutant embryos show losses of Eve expression, specifically within stripes 4, 5, and 6 (white arrows, T). (U, W) In wild type 
embryos, Wg is expressed in fourteen stripes of cells along the A–P axis. (V, X) Pcsgs m+z mutant embryos show both losses (black arrows, V, X) and aberrant 
patterning (white arrow, X) of these Wg stripes. patterning of other tissues in these embryos. For example, losses 
of Eve-expressing neurons in the CNS of pcs gs m+z mutant 
flies were observed (Fig. 2P) (Doe et al., 1988). This phenotype 
was unexpected because Pcs expression was not detected in 
wild type CNS. These data suggested a more general defect in 
early patterning and segmentation that could account for some of the mesoderm and muscle phenotypes described above. 
Therefore, we analyzed the expression of several classes of 
segmentation genes responsible for early embryonic patterning 
in pcs gs m+z embryos. 
We first analyzed expression of the gap gene Kr during 
segmentation in pcsgs m+z mutant embryos. In wild type 
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the embryo (Fig. 2Q) (Gaul and Jackle, 1987). This expression 
domain is established by overlapping gradients of expression of 
maternal effect genes, such as nos and bicoid (bcd) (Manseau 
and Schupbach, 1989). In pcs gs m+z mutant embryos, however, 
this expression domain was expanded posteriorly (Fig. 2R). 
Next, we examined expression of the pair-rule gene eve. Eve is 
expressed in seven stripes along the A–P axis in a wild type 
embryo during segmentation (Fig. 2S) (Frasch et al., 1987; 
Macdonald et al., 1986). These stripes of expression are 
established by overlapping expression of gap genes. In pcsgs 
m+z mutant embryos, reduced levels of Eve expression were 
observed, specifically in stripes 4, 5, and 6 (Fig. 2T). 
Finally, expression of the segment polarity genes wg and 
engrailed (en) was examined. During segmentation, Wg is 
expressed in fourteen stripes along the A–P axis of the 
embryo (Figs. 2U, W) (Gonzalez et al., 1991). In pcs gs m+z 
mutants, we observed missing or aberrantly patterned Wg 
stripes. These losses of Wg stripes are predominantly in the 
posterior of the embryo, but occasional losses were detected 
in the most anterior abdominal segments (Figs. 2V, X). 
These defects in Wg expression were first detected at stage 
8 and were maintained throughout subsequent development. 
In addition, we noted losses of En stripes in pcs gs m+z 
mutant embryos (data not shown). These data confirmed 
previously published results suggesting that pcs is required 
maternally for posterior patterning in the embryo (Sinka et 
al., 2002). 
The posterior patterning defects observed in pcs gs m+z 
mutant embryos were consistent with those predicted to be 
caused by a reduction of Osk levels at the posterior pole of the 
embryo. Indeed, Sinka et al. (2002) observed a reduction in 
Osk levels in pcsgs mutant embryos. As Osk localization at 
the posterior pole is established during oogenesis (Ephrussi et 
al., 1991), we next determined whether all aspects of the 
posterior patterning defects observed in pcs gs m+z mutant 
embryos were due to a maternal requirement for pcs. We thus 
collected pcs gs mat embryos, which lack all maternal 
expression of pcs, but express pcs zygotically (Fig. 3). 
When posterior patterning in pcs gs mat embryos was analyzed 
by examining expression of the gap gene Kr, we observed 
similar phenotypes to those seen in pcs gs m+z mutant 
embryos, namely an expansion in Kr expression towards the 
posterior of the embryo (Fig. 3E). We found the same defects 
described for pcs gs m+z mutant embryos for expression of the 
pair-rule gene eve (Fig. 3H) and the segment polarity gene wg 
(Fig. 3K). These data indicated that the posterior patterning 
defects described above are due specifically to a requirement 
for pcs during oogenesis. 
Loss of pcs during oogenesis causes global defects in 
mesodermal patterning 
We next addressed what aspects of the muscle defects 
described above were also due to a maternal requirement for 
pcs. We first analyzed early mesodermal patterning by 
looking at Twi expression. In pcs gs mat mutant embryos, we observed a reduction in Twi expression levels and a 
“twisting” phenotype identical to that observed in pcs gs m+z 
mutant embryos (compare Figs. 2J and 3N). This indicated 
that the defects in early mesodermal patterning described 
above were due to the loss of maternal Pcs expression. We 
next analyzed the final muscle pattern. In pcs gs mat mutant 
embryos, we observed incompletely penetrant and variable 
defects in the final muscle pattern. 37% of embryos showed a 
moderate to severe phenotype (Figs. 3Q, T, n =19) with the 
remaining mutant embryos showing mild to moderate defects. 
Muscle defects observed include muscle losses, unfused 
myoblasts, and defects in muscle morphology. The posterior 
segments were most severely affected, but curiously, anterior 
segments also displayed the same classes of patterning 
defects. 
We next asked whether the observed global loss of 
mesodermal patterning is caused by the defects in posterior 
patterning described above. There are two Osk protein 
isoforms expressed in the oocyte, a short 55 kDa isoform 
and a long 71 kDa isoform (Markussen et al., 1995). Western 
blot analysis of pcsgs mutant ovaries showed a significant 
reduction in levels of the short Osk isoform, while levels of 
the long Osk isoform were unaffected (Sinka et al., 2002). 
Previous studies have indicated that the short Osk isoform is 
necessary and sufficient to induce the formation of abdomen 
and germline within the embryo (Markussen et al., 1995). We 
therefore determined what effects specifically removing the 
short Osk isoform would have on both embryonic patterning 
and muscle development. To do this, we expressed a transgene 
encoding the long Osk isoform (oskM139L) in  osk 54/Df 
females, which express no Osk protein, and crossed them to 
yw males. The only Osk protein expressed in the ovaries 
and oocytes of those females is the long isoform. Embryos 
laid by oskM139L; osk 54/Df females show a reduction in Osk 
levels as previously described (Fig. 3C) (Markussen et al., 
1995). 
When we analyzed embryonic patterning in embryos laid 
by females only expressing the long Osk isoform, we saw 
identical classes of phenotypes to those observed in embryos 
laid by pcsgs mutant females. However, in all cases, the 
defects in oskM139; osk 54/Df mat embryos were more severe 
than those observed in pcs gs mat embryos. Kr expression 
was expanded towards the posterior of the embryo (Fig. 3F), 
and a complete loss of Eve expression in stripes 4, 5, and 6 
was observed (Fig. 3I). We also observed losses of Wg 
expression (Fig. 3L). However, analysis of these embryos was 
complicated by the “twisting” phenotype observed. This is 
similar to that observed in the pcs gs m+z and pcs gs mat 
mutant embryos described above and suggested a defect in 
Twi expression or mesodermal specification. Indeed, when we 
analyzed Twi expression, we observed a reduction in Twi 
levels, but not number of cells (Fig. 3O). We also observed 
severe defects in the final muscles in these embryos (Figs. 
3R, U). There is a dramatic reduction in the number of 
muscles, a large number of unfused myoblasts, and defects in 
muscle morphology. The defects in embryonic patterning and 
muscle development observed in embryos laid by females 
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Fig. 3. The pcsgs mat early patterning and muscle phenotypes are Osk-dependent. Wild type (A, D, G, J, M, P, S), pcsgs mat (B, E, H, K, N, Q, T), and oskM139L; 
osk54/Df mat (C, F, I, L, O, R, U) mutant embryos were stained with anti-Osk (A–C), anti-Kr (D–F), anti-Eve (G–I), anti-Wg (J–L), anti-Twist (M–O), and anti-MHC 
(P–U). All views are lateral except J–L, P–U which are ventral. (A) Osk protein is tightly localized to the posterior pole in wild type embryos (black arrow). (B) Pcsgs 
mat mutant embryos show decreased levels of Osk protein at the posterior pole (black arrow). (C) OskM139L; osk54/Df mat mutant embryos show lower levels of Osk 
protein than wild type (A) or pcsgs mat (B) embryos. (D, E) The Kr expression domain is expanded in pcsgs mat mutant embryos (black bracket, E) compared to wild 
gstype (black bracket, D). (F) Kr expression is expanded in oskM139L; osk54/Df mat mutant embryos (black bracket, F) more than observed in pcs mat mutant 
embryos (E). (G) Eve is expressed in seven stripes along the A–P axis in wild type embryos. (H, I) Losses of Eve expression are observed in both pcsgs mat (black 
arrows, H) and oskM139L; osk54/Df mat (black arrows, I) mutant embryos. (J, K) Pcsgs mat mutant embryos show losses of Wg stripes (black arrow, K) and aberrant 
patterning of remaining stripes (white arrow, K) compared to wild type (J). (L) oskM139L; osk54/Df mat mutant embryos show losses of Wg expression (black arrow, 
gsL). (M) Twist is expressed at high levels in all mesodermal cells at stage 9. (N, O) Twist levels are reduced in pcs mat (N) and oskM139L; osk54/Df mat mutant 
embryos (O). (P, S) Wild type embryos display a segmentally repeated pattern of ventral muscles. (Q, T) Pcsgs mat mutant embryos show general muscle patterning 
defects including missing muscles (black arrows, Q, T), unfused myoblasts (black arrowhead, Q, T), and muscle morphology problems (white arrows, Q, T). In 
addition these embryos display segment-specific defects (white bracket, Q, T). (R, U) oskM139L; osk54/Df mat mutant embryos show severe defects in muscle 
development. Large numbers of muscles are missing (black arrows, R, U), and unfused myoblasts are observed (black arrowhead, R, U). Defects in muscle 
morphology are also observed (white arrows, R, U). lacking the short isoform of Osk and those laid by females 
lacking Pcs expression were strikingly similar. Taken 
altogether, these data strongly suggested that the early patterning and muscle defects observed in pcs gs mat embryos 
were primarily due to a reduction in the levels of the short 
Osk isoform. 
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Fig. 4. The segment-specific defects observed in pcsgs mat mutant embryos are 
due to loss of Wg expression within that segment. Wild type (A, C, E, G, I), 
pcsgs mat mutant (B), and prd-GAL4>UAS-dnTCF (D, F, H, J) embryos were 
stained with anti-Wg (A–D), anti-Eve (A, B, E, F), or anti-MHC (G–J). Lateral 
views are shown except for C, D, G, I, which are ventral. (A) Wild type embryos 
show Wg expression in the dorsal epidermis (brown staining, A) directly 
overlying the Wg-dependent Eve-expressing FCs in the dorsal mesoderm (black 
staining, A) of each hemisegment at stage 11. (B) In pcsgs mat mutant embryos, 
loss of Wg expression in the epidermis corresponds to reduction in Eve 
expression in the mesoderm of the same hemisegment (black arrow, B). (C) Wild 
type embryos show normal Wg expression at stage 11. (D) prd-GAL4>UAS­
dnTCF embryos show reductions in Wg expression levels in prd-expressing 
segments (black arrows, D). (E) Eve is expressed in a subset of Wg-dependent 
FCs in the dorsal mesoderm of each hemisegment in wild type embryos. (F) 
Losses of Eve expression are observed in prd-expressing segments in prd­
GAL4>UAS-dnTCF embryos (black arrows, F). (G, I) Wild type ventral muscle 
pattern at stage 16. (H, J) prd-GAL4>UAS-dcTCF embryos show specific 
muscle defects in prd-expressing segments. These defects include loss of Wg­
dependent muscles (black arrows, H, J) and muscle morphology defects, 
especially in the lateral LT muscles, which appear shorter than usual (white 
arrows, H, J). Loss of Wg signaling causes segment-specific defects in 
patterning 
In addition to the global mesodermal patterning defects 
observed in the pcs gs mat mutant embryos, we observed 
segment-specific problems: one segment often had a more 
severe muscle phenotype than its adjacent segments. This 
severe phenotype included a dramatic loss of muscles and a 
large number of unfused myoblasts (Figs. 3N, Q). A possible 
explanation for these segment-specific defects could be effects 
on Wg expression described above. Much work has high­
lighted the requirement for Wg signaling from the ectoderm to 
pattern the mesoderm at multiple times during muscle 
development (Bate and Rushton, 1993; Baylies et al., 1995; 
Carmena et al., 1998; Cox and Baylies, 2005; Cox et al., 2005; 
Halfon et al., 2000; Knirr and Frasch, 2001; Ranganayakulu et 
al., 1996; Wu et al., 1995). One would therefore predict that 
loss of Wg signaling within a segment would cause loss of 
Wg-dependent cell types within that same segment. We thus 
analyzed the specification of Wg-dependent cell types— 
founder cells (FCs) and neurons—in pcs gs mat mutant 
embryos (Carmena et al., 1998; Doe et al., 1988). Losses of 
both cell types were found in a segment-specific manner: when 
Eve-positive FCs were absent, so were the Wg-dependent Eve-
positive cells in the CNS in the same segment (data not 
shown). Next, we correlated the losses of Eve-positive FCs 
with loss of Wg expression in the same segment. Eve-positive 
FCs arise in the dorsal mesoderm of each hemisegment at stage 
11. At this time, Wg is expressed in a cluster of dorsal 
ectodermal cells directly overlaying the Eve-expressing cluster 
(Fig. 4A). In pcs gs mat mutant embryos, we observed a 
correlation between Wg loss in the dorsal ectoderm and Eve-
positive FCs loss in the dorsal mesoderm of that same segment 
(Fig. 4B). 
Although these results supported our hypothesis that the 
segment-specific phenotypes observed in the muscle pattern of 
pcs gs mat mutant embryos were due to loss of Wg signaling, it 
did not confirm that the loss of Wg expression observed was 
directly responsible for the mesodermal phenotypes detected. 
To test this, we abolished Wg signaling in a segment-specific 
manner and determined if this reproduced the segment-specific 
phenotype observed in the final muscle pattern. Embryos 
expressing dnTCF driven by prd-GAL4 showed a roughly 50% 
reduction in Wg levels in prd-expressing segments in the 
ectoderm of stage 11 embryos (Materials and methods; Fig. 
4D) When we analyzed the specification of Wg-dependent cell 
types in the mesoderm, a reduction in the number of Eve-
positive FCs was found in prd-expressing segments (Fig. 4F). 
This could be due to either the reduction in Wg expression 
levels observed in the ectoderm of the embryos or a direct 
repression of the Wg target gene eve by dnTCF expression in 
the mesoderm (Halfon et al., 2000; Knirr and Frasch, 2001). 
Finally, we analyzed the final muscle pattern in these embryos; 
we observed the same segment-specific phenotype as 
described above (Figs. 4H, J). This phenotype, however, was 
not as severe as that observed in pcs gs mat mutant embryos 
(Figs. 3N, Q). This nevertheless supported our hypothesis that loss of Wg signaling within the segment contributed to the 
segment-specific defects observed in pcs gs mat mutant 
embryos. Hence, Wg is required in a segment-specific manner 
to specify Wg-dependent cell types in the mesoderm and other 
tissues. 
Correct levels of Pcs expression are required zygotically for 
muscle development 
While some of the muscle phenotypes observed in pcs gs 
m+z mutant embryos are due to a requirement for pcs during 
oogenesis, Pcs expression during muscle development 
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development. We therefore asked whether pcs is required 
zygotically for muscle development by analyzing embryos 
lacking zygotic expression of pcs but that have the maternal 
contribution of pcs. These embryos have normal posterior 
patterning, and we referred to them as pcs gs zyg mutant 
embryos. 
We found reproducible muscle defects, including missing 
muscles. For example, we observed losses of VO6, VL3, and 
DA1 muscles in some embryos (Figs. 6C, F, I). We also 
observed errors in muscle morphology in pcs gs zyg mutant 
embryos. Muscles are often not the correct size, shape, or 
orientation and attach incorrectly to the overlaying ectoderm 
(Figs. 5J, N and 6C, F). For example, muscle DT1 often attaches 
more anteriorly than it should (Fig. 6F). Losses of Eve-
expressing FCs (Fig. 5B) were found, corresponding to the 
missing DA1 muscles observed (Fig. 6I), indicating that pcs 
zygotic activity is required for FC specification and that this 
may account for the muscle losses observed in the final muscle 
pattern. As Pcs is not expressed in the Eve-expressing FCs (data 
not shown), we hypothesized that these FC losses were due to 
the loss of Pcs expression prior to FC specification. We Fig. 5. Correct levels of Pcs are required within the mesoderm for muscle specificatio
GAL4; Dmef 2-GAL4>UAS-pcsRNAi (C, G, K, O), and twi-GAL4; Dmef2-GAL4>UA
or anti-MHC (I–P). Panels A–D are lateral views of stage 11 embryos. Panels E–H 
embryos. Panels M–P are close-up views of the embryos shown in panels I–L. (A–D
subset of FCs in the dorsal mesoderm of each hemisegment in wild type embryos. (B)
Eve expression in twi-GAL4; Dmef2-GAL4>UAS-pcsRNAi embryos appears wild typ
between clusters (black arrowhead, D) and enlarged Eve clusters (data not shown). (E–
numbers of FCMs in each hemisegment. No defects in FCM specification are obser
Dmef2-GAL4>UAS-pcs (H) embryos. (I–P) Pcs is required for muscle specificatio
ventral muscle pattern. Pcsgs zyg mutant (J, N), twi-GAL4; Dmef2-GAL4>UAS-pcsRN
losses of muscles (black arrows, J–L, N–P) and defects in muscle morphology (whtherefore analyzed early mesodermal patterning in these 
embryos. However, Twist expression, the earliest marker for 
mesoderm, was wild type in pcs gs zyg mutant embryos, 
indicating that the mesoderm appeared to be specified and 
patterned correctly (data not shown). In support of this 
observation, visceral and cardiac mesoderm formation in these 
mutant embryos appeared normal (data not shown). Hence, Pcs 
could be acting on an early mesodermal regulator other than 
Twist or affecting Twist expression or activity in a way not 
detected by this assay. 
Pcs is specifically enriched in FCMs during muscle 
morphogenesis. We therefore analyzed FCM specification and 
differentiation by using an antibody against the FCM-specific 
protein Lameduck (Lmd, also known as Myoblasts incompetent 
or Gleeful) (Duan et al., 2001; Furlong et al., 2001; Ruiz-
Gomez et al., 2002). However, in pcs gs zyg mutant embryos, no 
defects in Lmd expression were observed (Fig. 5F), suggesting 
that FCM specification and differentiation occur normally. 
Together, these data indicated that pcs is required zygotically 
both for muscle specification and morphogenesis. 
To confirm that Pcs is required specifically within the 
mesoderm to establish the correct larval muscle pattern, we n and morphogenesis. Wild type (A, E, I, M), pcsgs zyg mutant (B, F, J, N), twi­
S-pcs (D, H, L, P) embryos were stained with anti-Eve (A–D), anti-Lmd (E–H), 
are lateral views of stage 12 embryos. Panels I–P are ventral views of stage 16 
) Pcs is required for FC specification. (A) The FC marker Eve is expressed in a 
 Pcsgs zyg mutant embryos show losses of Eve expression (black arrows, B). (C) 
e. (D) twi-GAL4; Dmef2-GAL4>UAS-pcs embryos show ectopic Eve expression 
H) Pcs is not required for FCM specification. (E) Wild type embryos show large 
ved in pcsgs zyg (F), twi-GAL4; Dmef2-GAL4>UAS-pcsRNAi (G) or twi-GAL4; 
n and morphogenesis. (I, M) Wild type embryos show a segmentally repeated 
Ai (K, O) and twi-GAL4; Dmef2-GAL4>UAS-pcs (L, P) embryos all show both 
ite arrowheads, J–L, N–P). 
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Fig. 6. Pcs is required maternally for global embryonic patterning and zygotically for muscle specification and morphogenesis. Wild type (A, D, G), pcsgs m+z (B, E, 
H), and pcsgs zyg (C, F, I) embryos were stained with an antibody against MHC. Ventral (A–C), lateral (D–F), and dorsal (G–I) views of stage 16 embryos are shown. 
(A, D, G) Wild type embryos show a segmentally repeated pattern of muscles. (A) The ventral muscles VO4, VO5, and VO6 point towards the posterior of the embryo 
(black arrows, A). (D) Muscles VL1, VL2, VL3, and VL4 span the hemisegment in wild type embryos (black arrows, D), while muscle DT1 runs transverse (black 
arrowheads, D). (G) Muscle DA1 spans the hemisegment at an acute angle (black arrows, G). (B, E, H) Pcsgs m+z show global defects in the final muscle pattern. 
Specific defects observed include muscle losses (red arrows, B, E), unfused myoblasts (white arrowheads, B, E, H), and defects in muscle morphology (white arrows, 
B, H). A large number of unfused myoblasts are observed (white arrowheads, B, E, H). (C, F, I) Pcsgs zyg mutant embryos show defects in the final muscle pattern. 
These defects vary between hemisegments and embryos, but include defects in muscle specification and morphogenesis. For example, losses of VO6 (red arrow, C), 
VL3 (red arrow, F), and DA1 (red arrow, I) muscles can be observed. In addition, muscles are often too small (white arrows, C, F) or the incorrect shape (blue arrow, C). 
In some cases, muscle attachment appears aberrant. For example, muscle DT1 often attaches more anteriorly than it should (black arrowheads, F). Occasional unfused 
myoblasts are also seen (white arrowhead, F). analyzed embryos in which pcs expression was specifically 
removed in the mesoderm by using RNAi (Piccin et al., 2001). 
A pcs RNAi transgene (Materials and methods) was expressed 
throughout the mesoderm at high levels using twi-GAL4; 
Dmef2-GAL4 drivers. We observed a 50% decrease in Pcs 
expression levels in the UAS-pcsRNAi expressing embryos 
compared to wild type, indicating that our UAS-pcsRNAi 
transgene reduces Pcs levels in vivo (Supplementary Fig. 1B). 
When the final muscle pattern was examined in these embryos, 
we found a similar phenotype to that observed in pcsgs zyg 
mutant embryos. Muscle losses and defects in muscle 
morphogenesis were observed (Figs. 5K, O), but FC (Fig. 5C) 
and FCM (Fig. 5G) specification occurred normally. We suggest 
that this discrepancy in the FC specification results is due to the 
delay in the GAL4/UAS (Brand and Perrimon, 1993) and RNAi 
(Piccin et al., 2001) systems; hence, sufficient Pcs protein was 
present prior to the time of FC specification for Eve expression 
to be normal. Nevertheless, these data confirmed that pcs is 
required specifically within the mesoderm for muscle specifica­
tion and morphogenesis. 
We next asked whether overexpression of Pcs protein would 
cause defects in muscle development. Analysis of the final 
muscle pattern in these embryos revealed both muscle losses 
and defects in muscle morphology. The muscles often appeared 
thin, and a subset of the ventral muscles approached the midline 
(Figs. 5L, P). Ectopic expression of Eve was observed between the normally discrete clusters of Eve-expressing FCs in the 
dorsal mesoderm (Fig. 5D) and occasional expansion of the 
Eve-expressing clusters was observed (data not shown). 
However, no defects in Lmd expression were observed (Fig. 
5H). Together, these data indicated that correct levels of Pcs are 
required specifically within the developing mesoderm for both 
muscle specification and morphogenesis. 
Pcs as a regulator of NRTK activity 
Pcs is the Drosophila orthologue of the mammalian Sab 
gene, which is known to inhibit the activation of BTK 
(Matsushita et al., 1998; Yamadori et al., 1999). Previous work 
has shown that the pcs grandchildless phenotype can be 
suppressed by reducing the maternal dosage of the BTK 
homologue Btk29A (Sinka et al., 2002). We also found that 
reducing the dose of Btk29A by half was sufficient to observe 
suppression of the pcs grandchildless phenotype (Table 1). We 
then asked whether reducing the maternal dosage of Btk29A 
by half could suppress the early patterning defects reflected in 
the loss of the pair-rule Eve and segment polarity Wg 
expression that were observed in pcs gs mat mutant embryos. 
Under these conditions, we again observed a suppression of 
the pcs gs mat mutant phenotype (Table 1). These results 
confirmed that Btk29A is a target of Pcs regulation during 
oogenesis. 
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Table 1 
Effect of reducing Btk29A dosage on pcsgs grandchildless, early patterning, and 
muscle phenotypes 
Grandchildless phenotype ⁎ 
Maternal genotype n Wild type Agametic 
pcsgs 109 7% 93% 
Btk29Ak00206, pcsgs/pcsgs 168 26% 74% 
Early patterning (Eve) ⁎⁎ 
Maternal genotype n Wild type Abnormal 
pcsgs 13 31% 69% 
Btk29Ak00206, pcsgs/pcsgs 44 50% 50% 
Early patterning (Wg) ⁎⁎ 
Maternal genotype n Wild type Agametic 
pcsgs 53 46% 54% 
Btk29Ak00206, pcsgs/pcsgs 40 80% 20% 
Muscle development ⁎⁎⁎ 
Parental genotype (F×M) n Wild type Abnormal 
pcsgs/CyO × pcsgs/CyO 25 92% 8% 
Btk29Ak00206, pcsgs/CyO × pcsgs/CyO 59 85% 15% 
⁎ p <0.001 for a Chi-squared test.

⁎⁎ p <0.05 for a Chi-squared test.

⁎⁎⁎ p >0.05 for a Chi-squared test.
We next addressed if this relationship between Pcs and 
Btk29A was maintained during muscle development. We first 
tested if Btk29A was expressed in the mesoderm during 
embryonic development. We found that Btk29A is expressed in 
the developing ectoderm, CNS, PNS, and tracheal pits, 
confirming previous studies (Fig. 7) (Carmena et al., 1995; 
Katzen et al., 1990; Vincent et al., 1989; Wadsworth et al., 
1990). We also observed Btk29A expression in migrating 
primordial germ cells. Interestingly, Btk29A expression in these 
cells was localized to the leading edge of the cell (data not 
shown). Btk29A expression in the developing mesoderm was 
examined by double staining embryos with Twist antibody 
(Figs. 7A–F). At stages 10 (Figs. 7A–C) and 11 (Figs. 7D–F), 
Btk29A expression was detected in a subset of Twist-expressing 
cells just underneath the overlaying ectoderm. At stage 11, these 
cells were located adjacent to the developing tracheal pit, where 
Btk29A is highly expressed (Figs. 7D–F). This mesodermal 
Btk29A expression then decreased and was absent by stage 13. 
We also investigated whether the mesodermal Btk29A 
expression was in FCs or FCMs. Btk29A expression was 
analyzed in a genetic background in which all FCs were 
labeled (rP298; Figs. 7G–I). In these embryos, Btk29A was 
expressed in only one FC at stage 13 (Fig. 7I). This FC was 
ventral and posterior to the tracheal pit within that segment and 
did not correspond to the ventral Pcs-expressing FC (data not 
shown). In addition to expression in a single FC, Btk29A was 
expressed in a small number of FCMs surrounding it, which 
also express Pcs. Later in mesodermal development, no muscle 
expression of Btk29A was found (Figs. 7J–L and data not 
shown). Taken together, these data indicated that Btk29A is 
expressed in a subset of mesodermal cells during mesodermal subdivision and FC specification and therefore could poten­
tially be regulated by Pcs at this time. However, these data also 
demonstrated that Btk29A is not expressed in the majority of 
Pcs-expressing cells during these stages of somatic muscle 
development. In addition, Btk29A is not detected in the 
mesoderm after stage 13 while Pcs is strongly expressed at this 
time and throughout the remainder of muscle morphogenesis. 
This suggested that Pcs has additional targets of regulation 
during muscle development. 
To confirm that Btk29A is not the major target of Pcs 
regulation during muscle development, we tested whether 
reducing Btk29A levels zygotically could suppress the pcs gs 
zyg mutant muscle phenotype. No difference in the penetrance of 
the muscle specification and morphogenesis phenotypes was 
observed between pcs gs zyg and Btk29Ak00206, pcs gs/pcs gs zyg 
mutant embryos (Table 1). In addition, we analyzed muscle 
development in Btk29Ak00206 homozygous mutant embryos and 
observed global defects in the final muscle pattern (data not 
shown). These defects do not correlate with the limited 
mesodermal expression of Btk29A or with Btk29A being a 
target of Pcs regulation during oogenesis. We hypothesized that 
this may be due to the requirement for Btk29A in other tissues 
such as the epidermis or CNS. To conclude, we have 
demonstrated that while Btk29A is the major target of Pcs 
regulation during oogenesis, it does not appear to be an 
important Pcs target during muscle development. 
Discussion 
This work highlights the phenomenon of reiterative gene 
usage by showing that a novel signaling protein, Pcs, is required 
at multiple times and places during Drosophila development. 
We have confirmed that Pcs is first required during oogenesis to 
establish anterior–posterior patterning in the developing 
embryo and that this initial axis determination is required for 
subsequent development of multiple tissues within the embryo. 
We also showed that Pcs is required again, specifically within 
the developing mesoderm of the embryo to regulate both muscle 
specification and morphogenesis (Fig. 8). 
Expression analysis initially identified the tissues where 
Pcs could play an important role. Previously described studies 
showed that Pcs is expressed in the ovary and developing 
oocyte (Sinka et al., 2002). We showed that, in the embryo, 
Pcs is predominantly expressed in the developing somatic 
mesoderm throughout muscle development. Pcs is expressed 
panmesodermally during specification of different mesoder­
mal tissues. Once somatic mesoderm is specified, Pcs 
expression becomes restricted to the developing somatic 
muscles where it is maintained throughout the remainder of 
development. Within the somatic mesoderm itself, we also 
demonstrated that Pcs is enriched in FCMs as predicted by the 
microarray screen from which it was isolated (Artero et al., 
2003). 
Genetic analysis has demonstrated a requirement for pcs 
during oogenesis and muscle development. We have shown that 
embryos lacking all maternal and zygotic pcs expression 
showed defects both in early patterning and muscle 
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Fig. 7. Btk29A is expressed in a subset of mesodermal cells prior to fusion. Confocal micrographs of wild type (A–F, J–L) and rP298 (G–I) embryos stained with anti­
Btk29A (green, A, D, G, J), anti-Twi (red, B, E), anti-β-gal (red, H), and anti-MHC (red, K). The merged images are shown in C, F, I, and L. Stage 10 (A–C), 11 (D–F), 
13 (G–I), and 16 (J–L) embryos are shown. Anterior is to the left and dorsal is up in all panels. (A–C) Btk29A is expressed at low levels in a subset of mesodermal cells 
(white arrows, C). (D–F) Btk29A expression is maintained in a subset of Twi-positive cells in the somatic mesoderm at stage 11 (white arrows, F). (G–I) Btk29A is 
then expressed in a single FC (white arrow, I) and surrounding FCMs at stage 13 as fusion begins. (J–L) Btk29A expression in the mesoderm disappears from late stage 
13 and is not present in the final muscles at stage 16, even though it is strongly expressed in the CNS and PNS (white arrows, L). development. Further genetic dissection has demonstrated that 
pcs is required maternally for early patterning and that this 
requirement for pcs can account for some defects observed in 
the mesoderm and other tissues of the embryo later in 
development (Fig. 8). We suggest that this maternal requirement 
for pcs is due to its requirement in the ovary. Sinka et al. (2002) 
showed rescue of the pcs grandchildless phenotype by specific 
expression of pcs in the ovary. In addition we examined the 
zygotic requirement for pcs and demonstrated that pcs is 
required specifically in the embryonic mesoderm for both 
muscle specification and morphogenesis. Therefore, not only is 
pcs required in two different tissues and two distinct times 
during development, but it is also required multiple times during 
the development of a specific tissue (Fig. 8). This places Pcs as 
an important player in multiple developmental processes, yet an 
important question remains as to how Pcs regulates these 
distinct processes. The role of Pcs during oogenesis 
One of the most striking results from this work is the 
demonstration that early patterning defects can cause very 
specific problems in the subsequent development of multiple 
tissues. Although gross embryonic patterning defects have been 
described in the offspring of females carrying mutations in pcs 
and other maternal genes required for early patterning, this has 
been determined by analyzing the final larval cuticle (Manseau 
and Schupbach, 1989; Sinka et al., 2002). This is one of the first 
studies, to our knowledge, that describes the specific defects in 
patterning of multiple tissues including the body wall muscles, 
cardiac and visceral mesoderm, CNS, and tracheal system (data 
not shown) caused by defects in early patterning. 
We observed defects in expression of maternal effect, gap, 
pair-rule, and segmentation genes in pcs gs mat mutant embryos, 
which indicates that the requirement for pcs is upstream of these 
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Fig. 8. Pcs function during Drosophila development. Pcs is required maternally for A–P patterning. A maternal loss of pcs activity causes defects in early patterning 
due to its role in regulating Osk. A subset are due to losses of Wg expression, which cause losses of Wg-dependent cell types in a segment-specific fashion. These early 
patterning defects cause global patterning defects in the embryo later in development. Genetic data indicate that the major target of maternal Pcs activity is the 
Drosophila Tec kinase Btk29A. Pcs is then required zygotically, specifically in the mesoderm, for both muscle specification and morphogenesis. Pcs is expressed 
throughout the mesoderm prior to its role in muscle specification. It then becomes enriched in FCMs, where we hypothesize that it is required for subsequent muscle 
morphogenesis. Genetic and expression data suggest that Btk29A is not the major target of zygotic Pcs activity. We propose that Pcs fulfils its zygotic role by 
regulating the activation of other NRTKs. factors. This correlates with the previously published work on 
pcs, which showed that pcs is required for correct levels of 
Osk protein at the posterior pole of early embryos (Sinka et al., 
2002). We have further shown that specific reduction in levels 
of the short Osk isoform can reproduce the early patterning and 
muscle defects observed in pcs gs mat mutant embryos. These 
data strongly suggest that the primary role of Pcs during 
oogenesis is in regulation of the levels of the short Osk isoform. 
However, it is formally possible that Pcs could regulate other 
factors required for early embryonic patterning. The early 
patterning and muscle defects observed in embryos laid by 
females only expressing the long Osk isoform are more severe 
and penetrant than those observed in pcs gs mat embryos. In 
particular, the majority of these embryos do not hatch in contrast 
to embryos laid by pcsgs mutant females that can survive to 
adulthood. Previous studies have shown that expression of the 
short Osk isoform is sufficient to rescue the patterning defects 
observed in embryos laid by osk54/Df females. These data 
presented here support that result and go further to show that the 
small amount of short Osk isoform remaining in pcsgs mutant 
ovaries is sufficient to partially rescue the osk54/Df phenotype. 
The role of Pcs in the mesoderm 
The embryonic expression pattern of Pcs and the pcs gs zyg 
mutant phenotype indicated that the major role of Pcs during 
embryogenesis is in regulating muscle development (Fig. 8). The expression of Pcs in the somatic mesoderm throughout this 
process suggested that pcs is required at multiple steps. This is 
supported by the phenotypic analysis which demonstrates that 
pcs is required both for muscle specification and morphogen­
esis. We propose that the loss of Pcs expression during 
mesodermal patterning and FC specification accounts for the 
defects in muscle specification, while the loss of Pcs expression 
in FCMs causes the muscle morphogenesis phenotype 
observed. This indicated that Pcs is reused at multiple times 
during the development of this specific germ layer, yet these 
data also suggested that the Pcs protein itself plays diverse roles. 
More specifically, Pcs is required both for specifying the fate of 
a subset of mesodermal cells and for the elaboration of that fate 
during muscle morphogenesis. Hence, the output of Pcs 
signaling may depend on context or the target of Pcs regulation 
(see below). 
Detailed analysis of Pcs expression showed an enrichment of 
Pcs in FCMs as predicted by the microarray screen from which 
it was identified (Artero et al., 2003). This occurs after FC 
specification and suggests that the expression of Pcs in FCMs 
may be required for its role in muscle morphogenesis. Several 
genes have been shown to be enriched specifically in FCMs and 
have been demonstrated to be required for myoblast fusion (sns 
and hbs) or FCM development (lame duck/myoblasts incompe­
tent) (Artero et al., 2001; Bour et al., 2000; Duan et al., 2001; 
Dworak et al., 2001; Ruiz-Gomez et al., 2002). Some of these 
genes have also been shown to play a role in muscle 
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demonstrated to be specifically required for this process. This 
provides further evidence to support the model put forward by 
Artero et al. (2003) that FCMs make their own contribution to 
regulating muscle morphogenesis. It also suggests that NRTK 
signaling is important for this process. To date, NRTK signaling 
has been shown to be important for the morphogenesis of 
several tissues in Drosophila development (Tsygankov, 2003). 
These data suggest a possible role for NRTK signaling in 
muscle development, which needs further investigation. 
Pcs as a regulator of NRTK signaling 
Pcs is the Drosophila orthologue of the mammalian Sab 
gene. Sab has been shown in vitro and in cell culture to bind 
and inhibit the activation of the BTK, the Drosophila 
homologue of which is Btk29A (Matsushita et al., 1998; 
Yamadori et al., 1999). A previous study has demonstrated a 
genetic link between pcs and Btk29A during oogenesis (Sinka 
et al., 2002). We have further gone on to show that reducing 
Btk29A levels maternally can also suppress the early patterning 
defects displayed by pcs gs mat mutant embryos. This indicates 
that Btk29A is the major target of Pcs regulation during 
oogenesis. 
However, the situation appears to be more complex during 
muscle development. We have shown that Btk29A is only 
expressed in a subset of mesodermal cells up to the time of FC 
specification, while Pcs is expressed panmesodermally at this 
time. In addition, Pcs is expressed during the rest of muscle 
development when Btk29A is absent. This suggests that Pcs 
must be acting independently of Btk29A. Indeed, genetic 
analysis does not support an interaction between pcs and 
Btk29A during muscle development. Therefore, we propose 
that, while Pcs may indeed regulate Btk29A activity in a 
subset of mesodermal cells early during muscle development, 
Pcs must have other targets. We hypothesize that these are 
other NRTKs and that the ability of Pcs to regulate multiple 
NRTKs at different times and places during development 
could account for its ability to regulate multiple processes. To 
support this hypothesis, a previous study has described 
expression of the NRTK Abl in differentiating muscles 
(Bennett and Hoffmann, 1992) and we have observed 
expression of both Src42A and Src64B throughout mesoder­
mal patterning, FC specification, and muscle morphogenesis 
(K.B. and M.K.B., unpublished results). It is therefore likely 
that NRTKs play important roles in regulating multiple steps 
of muscle development. Further study of these important 
signaling molecules should yield new insights into how these 
processes are controlled. 
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